Last updated: April 5, 2024
Sponsor: Hospital de Clinicas de Porto Alegre
Overall Status: Active - Recruiting
Phase
4
Condition
Pregnancy
Treatment
Methotrexate Sodium
Letrozole tablets
Clinical Study ID
NCT06354439
77015224.6.1001.5327
Ages > 18 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 18 years or older
- Diagnosis of ectopic pregnancy
- Desire for reproduction
- Ease of return
- Undetermined pregnancy location with abnormal hCG growth
- Presence of a heterogeneous adnexal mass on pelvic ultrasound suggestive of a tubalectopic pregnancy with an hCG level ≤ 3000 mIU/ml
- Absence of fetal cardiac activity
- Average diameter of the adnexal mass ≤ 3.5 cm
- Hemodynamically stable
- No significant abdominal pain (i.e, < 6 on a visual analog scale)
Exclusion
Exclusion Criteria:
- Presence of a significant amount of free fluid in the pelvis (as assessed by theultrasound technician)
- Allergy to methotrexate or letrozole
- A reduction in β-hCG ≥ 50% in 2 measurements with 48 hours between them or ≥ 85% in 4 days, or ≥ 95% in 7 days before randomization
- Abnormal liver function test (Alanine transaminase (ALT) ≥ 2 times the upper limit ofnormal)
- Abnormal renal function test (glomerular filtration rate ≤ 45 ml/min)
- Hemoglobin <10 g/dl
- Platelets <120.000/ml
- Presence of heterotopic pregnancy
- Do not wish to participate in the study.
Study Design
Total Participants: 130
Treatment Group(s): 2
Primary Treatment: Methotrexate Sodium
Phase: 4
Study Start date:
March 27, 2024
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
Hospital de Clínicas de Porto Alegre
Porto Alegre, RS 90035-903
BrazilActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.